The authors showed that the efficacy of immune-stimulatory gene therapy was enhanced in isocitrate-dehydrogenase 1 (mIDH1) gliomas, due to the reprogramming of the myeloid cells’ compartment infiltrating the tumor microenvironment.
[Science Advances]